It would seem to me that EXEL's co promotion option is to put a check on the sort of thing that was alleged to happen with Byetta, wherein Lilly shared profits with AMLN, but Lilly was alleged to not have promoted the drug with all zeal, and in fact was producing a competing drug in its own pipeline.With the right to copromote, EXEL could use its own sales force to sell the drug even if Roche deci